[Bcl-2 expression in testicular cancer in relation to tumor progression].
Bcl-2 expression has been studied extensively in a variety of human tumors. However, there are lack of clinical data in regard to its expression in germ cell testicular tumors (GCTTs). In this study we screened bcl-2 expression in 70 patient with GCTTs using the immunohistochemistry (IHC) and streptavidin biotin alkaline phosphatase method. Furthermore, we correlated this expression with metastatic behaviour and clinical stage. Overall, 41 (58%) carcinomas stained with anti-bcl-2 (DAKO-124) monoclonal antibody, By histologic type, these lesions included 11 (42.3%) of 26 seminomas (S) and 30 (68.18%) of 44 non seminomatous germ cell testicular tumors (NSGCT). The incidence of bcl-2 immunostaining was higher (P = 0.05, two-tailed, Fisher's test) in NSGCT than in seminomas. Bcl-2 expression was higher in tumors from metastatic patients than in tumors from metastatic-free patient (p = 0). There was a significant difference between the three stages of disease as to the expression of bcl-2 (chi 2 = 0). High level of bcl-2 was clearly dominant in tumors of advanced stages. The present finding revealed that bcl-2 expression occurs in GCTTs. Further, they suggested that bcl-2 is associated with a more progressed malignant phenotype in these tumors.
Eid
H
H
Országos Onkológiai Intézet, Budapest.
Gulyás
M
M
Mágori
A
A
Géczi
L
L
Bodrogi
I
I
Institioris
E
E
Bak
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D015870:Gene Expression; D019254:Genes, bcl-2 / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010641:Phenotype; D013736:Testicular Neoplasms / Q000235:genetics* / Q000276:immunology / Q000473:pathology / Q000601:surgery
Bcl-2 expresszió vizsgálata hererákokban, összefüggésben a tumorprogresszióval.